(Check out Carter’s worthcharting.com for actionable recommendations and live nightly videos.) Mid-cap biotech Immunovant is judged to be setup especially well for a move higher, by our work. In the throes of a “bearish-to-bullish” reversal, the stock exhibits bullish price-volume correlation and impressive relative strength to the market and to other biotechnology stocks. We’re buyers here. Price Objective: $40+/- This pair of identical charts of Immunovant tell the story: Source: FactSet DISCLOSURES: None. All opinions expressed by the CNBC Pro contributors are solely their opinions and do not reflect the opinions of CNBC, or its parent company or affiliates, and may have been previously disseminated by them on television, radio, internet or another medium. THIS CONTENT IS PROVIDED FOR INFORMATIONAL PURPOSES ONLY AND DOES NOT CONSTITUTE FINANCIAL, INVESTMENT, TAX OR LEGAL ADVICE OR A RECOMMENDATION TO BUY ANY SECURITY OR OTHER FINANCIAL ASSET. THE CONTENT IS GENERAL IN NATURE AND DOES NOT REFLECT ANY INDIVIDUAL’S UNIQUE PERSONAL CIRCUMSTANCES. THE ABOVE CONTENT MIGHT NOT BE SUITABLE FOR YOUR PARTICULAR CIRCUMSTANCES. BEFORE MAKING ANY FINANCIAL DECISIONS, YOU SHOULD STRONGLY CONSIDER SEEKING ADVICE FROM YOUR OWN FINANCIAL OR INVESTMENT ADVISOR. Click here for the full disclaimer.
Trending
- NoCFO Taps Salt Edge to Deliver in-App ‘Pay by Bank’ for SMEs in Finland and Germany
- Iran strikes will likely boost defense stocks — but here’s what will keep the cash flowing long after the conflict ends
- Corn Rallying on Friday | Nasdaq
- Dirty water, death and decline: the inside story of a privatisation scandal | Water
- Tether Freezes $4.2B in USDT Linked to Crime in 3 Years: Report
- Buy the Dip in Nvidia Stock After Q4 Earnings, or is it Too Soon?
- Something Big Just Happened in AI, Says Jensen Huang. Here’s What it Means for Nvidia.
- Where billionaire family offices placed their bets before the new year
Saturday, February 28
